

# Global Benign Prostatic Hyperplasia (BPH) Drugs Market Status and Outlook 2018-2025

<https://marketpublishers.com/r/GFC938BBCC4EN.html>

Date: August 2018

Pages: 136

Price: US\$ 4,000.00 (Single User License)

ID: GFC938BBCC4EN

## Abstracts

### REPORT SNAPSHOT

Key Content of Chapters (Including and can be customized, report is a semifinished version, and it takes 48-72 hours to upgrade)

Part 1:

Terminology Definition, Industry Chain, Industry Dynamics & Regulations and Global Market Overview

Part 2:

Upstream (Raw Materials / Components) & Manufacturing (Procurement Methods & Channels and Cost), Major Regional Production Overview and Trade Flow

Part 3:

Product Segment Overview and Market Status

Part 4:

Application / End-User Segment Overview and Market Status

Part 5:

Region Segment Overview and Market Status

Part 6:

Product & Application Segment Production & Demand by Region

Part 7:

Market Forecast by Product, Application & Region

Part 8:

Company information, Products & Services and Business Operation (Sales, Cost, Margin etc.)

Part 9:

Market Competition and Environment for New Entrants

Part 10:  
Conclusion

Market Segment as follows:

Key Companies

Astellas Pharma

Eli Lilly

GlaxoSmithKline

Sanofi

ADC Therapeutics

Bayer HealthCare

Bristol-Myers Squibb

Valeant Pharmaceuticals

Endo Pharmaceuticals

Foresee Pharmaceuticals

Madrigal Pharmaceuticals

Merck

Novartis

Spectrum Pharmaceuticals

Takeda Pharmaceuticals

Teva

Advaxis

ANI Pharmaceuticals

BHR Pharma

#### Market by Type

Alpha-blocker

Phosphodiesterase Type-5 Inhibitors

5-alpha-Reductase Inhibitors

#### Market by Application

Hospitals

Clinics

Others

## Contents

### **PART 1 INDUSTRY OVERVIEW (200 USD)**

- 1.1 Benign Prostatic Hyperplasia (BPH) Drugs Industry
  - 1.1.1 Market Development
  - 1.1.2 Terminology Definition in the Report
    - 1.1.2.1 Production
    - 1.1.2.2 Demand
    - 1.1.2.3 Sales Revenue
    - 1.1.2.4 Ex-factory Price & Sales Price
    - 1.1.2.5 Cost
    - 1.1.2.6 Gross Margin
- 1.2 Products & Services Scope
- 1.3 Industry Chain
- 1.4 Industry Dynamics & Regulations
- 1.5 Global Market Overview

### **PART 2 UPSTREAM & PRODUCTION (200 USD)**

- 2.1 Raw Materials / Components
- 2.2 Procurement Methods & Channels
- 2.3 Cost Structure & Manufacturing
- 2.4 Industry Capacity
- 2.5 Production Distribution by Geography
  - 2.5.1 Production in Major Regions / Countries
  - 2.5.2 Trade Flow Overview

### **PART 3 PRODUCT SEGMENT (400 USD)**

- 3.1 Introduction by Type
  - 3.1.1 Alpha-blocker
  - 3.1.2 Phosphodiesterase Type-5 Inhibitors
  - 3.1.3 5-alpha-Reductase Inhibitors
- 3.2 Market Status

### **PART 4 APPLICATION / END-USER SEGMENT (400 USD)**

- 4.1 Introduction by Application

- 4.1.1 Hospitals
- 4.1.2 Clinics
- 4.1.3 Others
- 4.2 Market Status

## **PART 5 REGIONAL MARKET (600 USD)**

### 5.1 Market Overview

### 5.2 by Region

#### 5.2.1 North America

- 5.2.1.1 United States Market Size and Growth (2015-2018E)
- 5.2.1.2 Canada Market Size and Growth (2015-2018E)
- 5.2.1.3 Mexico Market Size and Growth (2015-2018E)

#### 5.2.2 Europe

- 5.2.2.1 Germany Market Size and Growth (2015-2018E)
- 5.2.2.2 UK Market Size and Growth (2015-2018E)
- 5.2.2.3 France Market Size and Growth (2015-2018E)
- 5.2.2.4 Italy Market Size and Growth (2015-2018E)
- 5.2.2.5 Spain Market Size and Growth (2015-2018E)
- 5.2.2.6 Netherlands Market Size and Growth (2015-2018E)
- 5.2.2.7 Poland Market Size and Growth (2015-2018E)
- 5.2.2.8 Belgium Market Size and Growth (2015-2018E)
- 5.2.2.9 Sweden Market Size and Growth (2015-2018E)
- 5.2.2.10 Austria Market Size and Growth (2015-2018E)
- 5.2.2.11 Denmark Market Size and Growth (2015-2018E)
- 5.2.2.12 Switzerland Market Size and Growth (2015-2018E)
- 5.2.2.13 Russia Market Size and Growth (2015-2018E)

#### 5.2.3 Asia-Pacific

- 5.2.3.1 China Market Size and Growth (2015-2018E)
- 5.2.3.2 India Market Size and Growth (2015-2018E)
- 5.2.3.3 Japan Market Size and Growth (2015-2018E)
- 5.2.3.4 Korea Market Size and Growth (2015-2018E)
- 5.2.3.5 Australia Market Size and Growth (2015-2018E)
- 5.2.3.6 Indonesia Market Size and Growth (2015-2018E)
- 5.2.3.7 Thailand Market Size and Growth (2015-2018E)
- 5.2.3.8 Malaysia Market Size and Growth (2015-2018E)
- 5.2.3.9 Singapore Market Size and Growth (2015-2018E)
- 5.2.3.10 Philippines Market Size and Growth (2015-2018E)

#### 5.2.4 South America

- 5.2.4.1 Brazil Market Size and Growth (2015-2018E)
- 5.2.4.2 Argentina Market Size and Growth (2015-2018E)
- 5.2.4.3 Columbia Market Size and Growth (2015-2018E)
- 5.2.4.4 Chile Market Size and Growth (2015-2018E)
- 5.2.4.5 Peru Market Size and Growth (2015-2018E)
- 5.2.4.6 Puerto Rico Market Size and Growth (2015-2018E)
- 5.2.4.7 Ecuador Market Size and Growth (2015-2018E)
- 5.2.5 Middle East
  - 5.2.5.1 Saudi Arabia Market Size and Growth (2015-2018E)
  - 5.2.5.2 Iran Market Size and Growth (2015-2018E)
  - 5.2.5.3 UAE Market Size and Growth (2015-2018E)
  - 5.2.5.4 Oman Market Size and Growth (2015-2018E)
  - 5.2.5.5 Kuwait Market Size and Growth (2015-2018E)
  - 5.2.5.6 Iraq Market Size and Growth (2015-2018E)
  - 5.2.5.7 Turkey Market Size and Growth (2015-2018E)
- 5.2.6 Africa
  - 5.2.6.1 South Africa Market Size and Growth (2015-2018E)
  - 5.2.6.2 Egypt Market Size and Growth (2015-2018E)
  - 5.2.6.3 Nigeria Market Size and Growth (2015-2018E)
  - 5.2.6.4 Algeria Market Size and Growth (2015-2018E)
  - 5.2.6.5 Angola Market Size and Growth (2015-2018E)
  - 5.2.6.6 Morocco Market Size and Growth (2015-2018E)
  - 5.2.6.7 Sudan Market Size and Growth (2015-2018E)

## **PART 6 MARKET SUBDIVISION (800 USD)**

- 6.1 Regional Production
  - 6.1.1 Production by Type
    - 6.1.1.1 Alpha-blocker Production by Region
    - 6.1.1.2 Phosphodiesterase Type-5 Inhibitors Production by Region
    - 6.1.1.3 5-alpha-Reductase Inhibitors Production by Region
  - 6.1.2 Production by Application
    - 6.1.2.1 Hospitals Production by Region
    - 6.1.2.2 Clinics Production by Region
    - 6.1.2.3 Others Production by Region
- 6.2 Regional Demand
  - 6.2.1 Demand by Type
    - 6.2.1.1 Alpha-blocker Demand by Region
    - 6.2.1.2 Phosphodiesterase Type-5 Inhibitors Demand by Region

- 6.2.1.3 5-alpha-Reductase Inhibitors Demand by Region
- 6.2.2 Demand by Application
  - 6.2.2.1 Hospitals Demand by Region
  - 6.2.2.2 Clinics Demand by Region
  - 6.2.2.3 Others Demand by Region

## **PART 7 MARKET FORECAST (200 USD)**

- 7.1 Global Forecast
- 7.2 Forecast by Type
- 7.3 Forecast by Application
- 7.4 Forecast by Region

## **PART 8 KEY COMPANIES LIST (600 USD)**

- 8.1 Astellas Pharma
  - 8.1.2 Company Information
  - 8.1.2 Products & Services
  - 8.1.3 Business Operation
- 8.2 Eli Lilly
  - 8.2.1 Company Information
  - 8.2.2 Products & Services
  - 8.2.3 Business Operation
- 8.3 GlaxoSmithKline
  - 8.3.1 Company Information
  - 8.3.2 Products & Services
  - 8.3.3 Business Operation
- 8.4 Sanofi
  - 8.4.1 Company Information
  - 8.4.2 Products & Services
  - 8.4.3 Business Operation
- 8.5 ADC Therapeutics
  - 8.5.1 Company Information
  - 8.5.2 Products & Services
  - 8.5.3 Business Operation
- 8.6 Bayer HealthCare
  - 8.6.1 Company Information
  - 8.6.2 Products & Services
  - 8.6.3 Business Operation

- 8.7 Bristol-Myers Squibb
  - 8.7.1 Company Information
  - 8.7.2 Products & Services
  - 8.7.3 Business Operation
- 8.8 Valeant Pharmaceuticals
  - 8.8.1 Company Information
  - 8.8.2 Products & Services
  - 8.8.3 Business Operation
- 8.9 Endo Pharmaceuticals
  - 8.9.1 Company Information
  - 8.9.2 Products & Services
  - 8.9.3 Business Operation
- 8.10 Foresee Pharmaceuticals
  - 8.10.1 Company Information
  - 8.10.2 Products & Services
  - 8.10.3 Business Operation
- 8.11 Madrigal Pharmaceuticals
- 8.12 Merck
- 8.13 Novartis
- 8.14 Spectrum Pharmaceuticals
- 8.15 Takeda Pharmaceuticals
- 8.16 Teva
- 8.17 Advaxis
- 8.18 ANI Pharmaceuticals
- 8.19 BHR Pharma

## **PART 9 COMPANY COMPETITION (500 USD)**

- 9.1 Market by Company
- 9.2 Price & Gross Margin
- 9.3 Competitive Environment for New Entrants
  - 9.3.1 Michael Porter's Five Forces Model
  - 9.3.2 SWOT

## **PART 10 RESEARCH CONCLUSION (100 USD)**



## List Of Tables

### LIST OF TABLES

- Table Benign Prostatic Hyperplasia (BPH) Drugs Industry Dynamics & Regulations List
- Table Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Revenue, Cost and Margin, 2015-2018E
- Table Global Benign Prostatic Hyperplasia (BPH) Drugs Market Status by Type 2015-2018E, in USD Million
- Table Global Benign Prostatic Hyperplasia (BPH) Drugs Market Status by Application 2015-2018E, in USD Million
- Table Global Benign Prostatic Hyperplasia (BPH) Drugs Market Status by Application 2015-2018E, in Volume
- Table Global Benign Prostatic Hyperplasia (BPH) Drugs Market by Region 2015-2018E, in USD Million
- Table Global Benign Prostatic Hyperplasia (BPH) Drugs Market Share by Region in 2018, in USD Million
- Table Global Benign Prostatic Hyperplasia (BPH) Drugs Market by Region 2015-2018E, in Volume
- Table Global Benign Prostatic Hyperplasia (BPH) Drugs Market Share by Region in 2018, in Volume
- Table Alpha-blocker Production Value by Region 2015-2018E, in USD Million
- Table Alpha-blocker Production Volume by Region 2015-2018E, in Volume
- Table Phosphodiesterase Type-5 Inhibitors Production Value by Region 2015-2018E, in USD Million
- Table Phosphodiesterase Type-5 Inhibitors Production Volume by Region 2015-2018E, in Volume
- Table 5-alpha-Reductase Inhibitors Production Value by Region 2015-2018E, in USD Million
- Table 5-alpha-Reductase Inhibitors Production Volume by Region 2015-2018E, in Volume
- Table Hospitals Production Value by Region 2015-2018E, in USD Million
- Table Hospitals Production Volume by Region 2015-2018E, in Volume
- Table Clinics Production Value by Region 2015-2018E, in USD Million
- Table Clinics Production Volume by Region 2015-2018E, in Volume
- Table Others Production Value by Region 2015-2018E, in USD Million
- Table Others Production Volume by Region 2015-2018E, in Volume
- Table Alpha-blocker Market Size by Region 2015-2018E, in USD Million
- Table Alpha-blocker Market Size by Region 2015-2018E, in Volume

Table Phosphodiesterase Type-5 Inhibitors Market Size by Region 2015-2018E, in USD Million

Table Phosphodiesterase Type-5 Inhibitors Market Size by Region 2015-2018E, in Volume

Table 5-alpha-Reductase Inhibitors Market Size by Region 2015-2018E, in USD Million

Table 5-alpha-Reductase Inhibitors Market Size by Region 2015-2018E, in Volume

Table Hospitals Market Size by Region 2015-2018E, in USD Million

Table Hospitals Market Size by Region 2015-2018E, in Volume

Table Clinics Market Size by Region 2015-2018E, in USD Million

Table Clinics Market Size by Region 2015-2018E, in Volume

Table Others Market Size by Region 2015-2018E, in USD Million

Table Others Market Size by Region 2015-2018E, in Volume

Table Global Benign Prostatic Hyperplasia (BPH) Drugs Forecast by Type 2019F-2025F, in USD Million

Table Benign Prostatic Hyperplasia (BPH) Drugs Forecast by Type 2019F-2025F, in Volume

Table Benign Prostatic Hyperplasia (BPH) Drugs Market Forecast by Application / End-User 2019F-2025F, in USD Million

Table Benign Prostatic Hyperplasia (BPH) Drugs Market Forecast by Application / End-User 2019F-2025F, in Volume

Table Benign Prostatic Hyperplasia (BPH) Drugs Market Forecast by Region 2019F-2025F, in USD Million

Table Benign Prostatic Hyperplasia (BPH) Drugs Market Forecast by Region 2019F-2025F, in Volume

Table Astellas Pharma Information

Table Benign Prostatic Hyperplasia (BPH) Drugs Sales, Cost, Margin of Astellas Pharma

Table Eli Lilly Information

Table Benign Prostatic Hyperplasia (BPH) Drugs Sales, Cost, Margin of Eli Lilly

Table GlaxoSmithKline Information

Table Benign Prostatic Hyperplasia (BPH) Drugs Sales, Cost, Margin of GlaxoSmithKline

Table Sanofi Information

Table Benign Prostatic Hyperplasia (BPH) Drugs Sales, Cost, Margin of Sanofi

Table ADC Therapeutics Information

Table Benign Prostatic Hyperplasia (BPH) Drugs Sales, Cost, Margin of ADC Therapeutics

Table Bayer HealthCare Information

Table Benign Prostatic Hyperplasia (BPH) Drugs Sales, Cost, Margin of Bayer

**HealthCare**

Table Bristol-Myers Squibb Information

Table Benign Prostatic Hyperplasia (BPH) Drugs Sales, Cost, Margin of Bristol-Myers Squibb

Table Valeant Pharmaceuticals Information

Table Benign Prostatic Hyperplasia (BPH) Drugs Sales, Cost, Margin of Valeant Pharmaceuticals

Table Endo Pharmaceuticals Information

Table Benign Prostatic Hyperplasia (BPH) Drugs Sales, Cost, Margin of Endo Pharmaceuticals

Table Foresee Pharmaceuticals Information

Table Benign Prostatic Hyperplasia (BPH) Drugs Sales, Cost, Margin of Foresee Pharmaceuticals

Table Madrigal Pharmaceuticals Information

Table Benign Prostatic Hyperplasia (BPH) Drugs Sales, Cost, Margin of Madrigal Pharmaceuticals

Table Merck Information

Table Benign Prostatic Hyperplasia (BPH) Drugs Sales, Cost, Margin of Merck

Table Novartis Information

Table Benign Prostatic Hyperplasia (BPH) Drugs Sales, Cost, Margin of Novartis

Table Spectrum Pharmaceuticals Information

Table Benign Prostatic Hyperplasia (BPH) Drugs Sales, Cost, Margin of Spectrum Pharmaceuticals

Table Takeda Pharmaceuticals Information

Table Benign Prostatic Hyperplasia (BPH) Drugs Sales, Cost, Margin of Takeda Pharmaceuticals

Table Teva Information

Table Benign Prostatic Hyperplasia (BPH) Drugs Sales, Cost, Margin of Teva

Table Advaxis Information

Table Benign Prostatic Hyperplasia (BPH) Drugs Sales, Cost, Margin of Advaxis

Table ANI Pharmaceuticals Information

Table Benign Prostatic Hyperplasia (BPH) Drugs Sales, Cost, Margin of ANI Pharmaceuticals

Table BHR Pharma Information

Table Benign Prostatic Hyperplasia (BPH) Drugs Sales, Cost, Margin of BHR Pharma

Table Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Revenue by Company 2015-2017, in USD Million

Table Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Volume by Company 2015-2017, in Volume

Table Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Volume by Company in 2018, in Volume

## List Of Figures

### LIST OF FIGURES

Figure Benign Prostatic Hyperplasia (BPH) Drugs Picture

Figure Benign Prostatic Hyperplasia (BPH) Drugs Industry Chain Diagram

Figure Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Revenue 2015-2018E, in USD Million

Figure Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Volume 2015-2018E, in Volume

Figure Global Benign Prostatic Hyperplasia (BPH) Drugs Market Status by Type 2015-2018E, in Volume

Figure North America Benign Prostatic Hyperplasia (BPH) Drugs Market Size and Growth 2015-2018E, in USD Million

Figure North America Benign Prostatic Hyperplasia (BPH) Drugs Market Size and Growth 2015-2018E, in Volume

Figure Europe Benign Prostatic Hyperplasia (BPH) Drugs Market Size and Growth 2015-2018E, in USD Million

Figure Europe Benign Prostatic Hyperplasia (BPH) Drugs Market Size and Growth 2015-2018E, in Volume

Figure Asia-Pacific Benign Prostatic Hyperplasia (BPH) Drugs Market Size and Growth 2015-2018E, in USD Million

Figure Asia-Pacific Benign Prostatic Hyperplasia (BPH) Drugs Market Size and Growth 2015-2018E, in Volume

Figure South America Benign Prostatic Hyperplasia (BPH) Drugs Market Size and Growth 2015-2018E, in USD Million

Figure South America Benign Prostatic Hyperplasia (BPH) Drugs Market Size and Growth 2015-2018E, in Volume

Figure Middle East Benign Prostatic Hyperplasia (BPH) Drugs Market Size and Growth 2015-2018E, in USD Million

Figure Middle East Benign Prostatic Hyperplasia (BPH) Drugs Market Size and Growth 2015-2018E, in Volume

Figure Africa Benign Prostatic Hyperplasia (BPH) Drugs Market Size and Growth 2015-2018E, in USD Million

Figure Africa Benign Prostatic Hyperplasia (BPH) Drugs Market Size and Growth 2015-2018E, in Volume

Figure Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Revenue Forecast 2019F-2025F, in USD Million

Figure Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Volume Forecast

2019F-2025F, in Volume

Figure Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Price Forecast

2019F-2025F

Figure Global Benign Prostatic Hyperplasia (BPH) Drugs Gross Margin Forecast

2019F-2025F

Figure Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Revenue by Company  
in 2018, in USD Million

Figure Global Benign Prostatic Hyperplasia (BPH) Drugs Price by Company in 2018

Figure Global Benign Prostatic Hyperplasia (BPH) Drugs Gross Margin by Company in  
2018

## I would like to order

Product name: Global Benign Prostatic Hyperplasia (BPH) Drugs Market Status and Outlook 2018-2025

Product link: <https://marketpublishers.com/r/GFC938BBCC4EN.html>

Price: US\$ 4,000.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/GFC938BBCC4EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970